(Q33956728)

30 July 2017

1 reference

title

HMG-CoA reductase inhibitors and myotoxicity (English)

1 reference

30 July 2017

M Ucar

1

1 reference

30 July 2017

T Mjörndal

series ordinal

2

1 reference

30 July 2017

R Dahlqvist

series ordinal

3

1 reference

30 July 2017

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

22

1 reference

30 July 2017

6

1 reference

30 July 2017

441-457

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200022060-00003

30 July 2017

0 references

cites work

HMG-CoA reductase inhibitor therapy and peripheral neuropathy

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200022060-00003

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

21 January 2018

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

12 December 2020

In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes

1 reference

12 December 2020

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

1 reference

12 December 2020

CYP3A gene expression in human gut epithelium

1 reference

12 December 2020

Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin

1 reference

12 December 2020

High-density lipoprotein--the clinical implications of recent studies

1 reference

12 December 2020

Binding of drugs to human muscle

1 reference

12 December 2020

A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.

1 reference

12 December 2020

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

1 reference

12 December 2020

Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database

1 reference

12 December 2020

Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient

1 reference

12 December 2020

Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial

1 reference

12 December 2020

Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Rhabdomyolysis in autosomal dominant progressive external ophthalmoplegia

1 reference

12 December 2020

Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy

1 reference

12 December 2020

A review of current clinical findings with fluvastatin

1 reference

12 December 2020

Coronary risk factors, endothelial function, and atherosclerosis: a review

1 reference

12 December 2020

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? West Of Scotland Coronary Prevention Study.

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography

1 reference

12 December 2020

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

12 December 2020

HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies

1 reference

12 December 2020

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

12 December 2020

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on human gut mucosa

1 reference

12 December 2020

Rhabdomyolysis associated with acute Q fever

1 reference

12 December 2020

Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors

1 reference

12 December 2020

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

1 reference

12 December 2020

Polymyositis associated with simvastatin

1 reference

12 December 2020

A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine palmityl transferase

1 reference

12 December 2020

Updated clinical safety experience with fluvastatin

1 reference

12 December 2020

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

1 reference

12 December 2020

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

1 reference

12 December 2020

Clofibrate-induced muscular syndrome. Case report with ultrastructural findings and review of the literature.

1 reference

12 December 2020

Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers

1 reference

12 December 2020

Experimental simvastatin-induced myopathy in rabbits

1 reference

12 December 2020

Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits

1 reference

12 December 2020

Variability in creatine kinase: methodological, exercise, and clinically related factors

1 reference

12 December 2020

Acute Muscular Syndrome Associated with Administration of Clofibrate

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Drug-induced myopathies in man

1 reference

12 December 2020

Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin

1 reference

12 December 2020

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

1 reference

12 December 2020

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

12 December 2020

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

12 December 2020

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

1 reference

12 December 2020

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

1 reference

12 December 2020

Rhabdomyolysis due to interaction of simvastatin with mibefradil

1 reference

12 December 2020

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

1 reference

12 December 2020

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

1 reference

12 December 2020

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

1 reference

12 December 2020

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

12 December 2020

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

1 reference

12 December 2020

Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy

1 reference

12 December 2020

Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children

1 reference

12 December 2020

Effects of exercise and lovastatin on serum creatine kinase activity

1 reference

12 December 2020

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

1 reference

12 December 2020

Endothelial dysfunction and atherothrombotic occlusive disease.

1 reference

12 December 2020

Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

1 reference

12 December 2020

Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil

1 reference

12 December 2020

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

1 reference

12 December 2020

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

1 reference

12 December 2020

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

12 December 2020

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

12 December 2020

[Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity]

1 reference

12 December 2020

Changes in population cholesterol levels and coronary heart disease deaths in seven countries.

1 reference

12 December 2020

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine

1 reference

12 December 2020

Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems

1 reference

12 December 2020

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Peripheral neuropathy associated with simvastatin

1 reference

12 December 2020

Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450

1 reference

12 December 2020

Drug-induced rhabdomyolysis--mechanisms and management

1 reference

12 December 2020

Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors

1 reference

12 December 2020

A Skeletal-Muscle Disorder Associated with Intermittent Symptoms and a Possible Defect of Lipid Metabolism

1 reference

12 December 2020

Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors

1 reference

12 December 2020

Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin

1 reference

12 December 2020

Pravastatin-Associated Inflammatory Myopathy

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Cholesterol metabolism in man

1 reference

12 December 2020

Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients

1 reference

12 December 2020

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome

1 reference

12 December 2020

The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis

1 reference

12 December 2020

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

1 reference

12 December 2020

LDL-cholesterol as a determinant of coronary heart disease

1 reference

12 December 2020

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

1 reference

12 December 2020

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

12 December 2020

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

1 reference

12 December 2020

Case report: severe hyponatremia after water intoxication: a potential cause of rhabdomyolysis

1 reference

12 December 2020

New approaches to the prevention of atherosclerosis

1 reference

12 December 2020

Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects

1 reference

12 December 2020

Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease

1 reference

12 December 2020

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue

1 reference

12 December 2020

Effect of age and gender on pharmacokinetics of atorvastatin in humans.

1 reference

12 December 2020

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

1 reference

12 December 2020

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

12 December 2020

Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers.

1 reference

12 December 2020

Drug-interaction-induced rhabdomyolysis

1 reference

12 December 2020

10.2165/00002018-200022060-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1039668089

0 references

Fatcat ID

release_tekls77rr5dl7o4cgpp23sczw4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tekls77rr5dl7o4cgpp23sczw4

24 November 2022

mapped directly with Wikidata item

1 reference